MedTrace Logo

Preventive Effects of Cetylpyridinium Chloride on SarcopeniaStudy

NCT02297997 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2021-03-29

No results posted yet for this study

Summary

This study is to assess the impact on the prevention of sarcopenia after taking cetylpyridinium chloride targeting the patients of presarcopenia over the age of 60.

Conditions

Interventions

DRUG

cetylpyridinium chloride

Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.

DRUG

Placebo

Control group takes the placebo for the same period.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Sun Gun Chung, MD, PhD · Seoul National University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-13
Primary Completion
2015-11-30
Completion
2015-11-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02297997 on ClinicalTrials.gov